FindTrial
Sign In

Shenzhen Waldenstrom Macroglobulinemia Multicenter Real-world Study: Molecular Characteristics, Treatment Modalities and Clinical Decision Optimization

Shenzhen Waldenstrom Macroglobulinemia Multicenter Real-world Study: Molecular Characteristics, Treatment Modalities and Clinical Decision Optimization

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600119152
Enrollment
Unknown
Registered
2026-02-24
Start date
2026-03-02
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Waldenström's Macroglobulinemia

Interventions

Group 3(Genotype Unknown):None
Group 1(MYD88 Wild-Type):None
Group 2 (CXCR4 Mutant):None

Sponsors

Peking University Shenzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >=18 years old, gender not limited; 2.Patients with previously untreated or relapsed Waldenström's macroglobulinemia diagnosed according to established diagnostic criteria.

Exclusion criteria

Exclusion criteria: 1. Transformation to DLBCL; 2. Presence of concomitant malignancies.

Design outcomes

Primary

MeasureTime frame
Safety Outcomes;Complete remission;Partial relief;Micro reaction;Overall survival;Incidence of disease progression;Progression-free survival;Objective Response Rate;Very Good Partial Remission (VGPR);Stable disease;—

Secondary

MeasureTime frame
Primary Response Rate;—

Countries

China

Contacts

Public ContactQian Zhang

Peking University Shenzhen Hospital

herpes@126.com+86 755 83923333

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026